All In Biotech

NDA 212728 · Pfizer

Nurtec Odt

Rimegepant Sulfate · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Feb 27, 2020

Approved uses

3

Original approval plus efficacy supplements

Registered trials

50

19 Phase 3, 16 recruiting

FAERS reports

13,010

2,564 serious, 116 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 4, 2026.

NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults ( 1.1 ) • preventive treatment of episodic migraine in adults ( 1.2 ) 1.1 Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults . 1.2 Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.

Mechanism: Rimegepant is a calcitonin gene-related peptide receptor antagonist.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 11, 2022 Supplement 9 · Efficacy LetterLabel
  • May 27, 2021 Supplement 6 · Efficacy LabelLetter
  • Feb 27, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • NURTEC ODT · RIMEGEPANT SULFATE EQ 75MG BASE · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rimegepant" as an intervention, any sponsor and status, largest first.

All 50 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,108
  • nausea1,207
  • migraine885
  • headache789
  • therapeutic product effect incomplete649
  • off label use520
  • dizziness464
  • fatigue463
  • vomiting396
  • feeling abnormal330
  • pain312
  • product dose omission issue304

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20152
20161
20176
20188
201911
2020675
20211,995
20223,581
20232,081
20241,895
20251,715
20261,040

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nurtec ODT (Rimegepant Sulfate)

2024 spending

$625M

Beneficiaries

105,323

426,648 claims

Per beneficiary

$5,936

$123.77 per unit

View as table
YearSpending
2020$18,933,232
2021$118,402,787
2022$276,493,155
2023$478,240,312
2024$625,230,826

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 73 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.